Idebenone Mitigates Gene Expression Changes After Traumatic Brain Injury: Focus on Ephrin-A and Dopamine Pathways
Source
Cells, 2025 Jun 01, DOI: 10.3390/cells14110824
Traumatic brain injury (TBI) triggers persistent pro-inflammatory microglial activation that contributes to long-term neurodegeneration. Idebenone, a synthetic coenzyme Q10 analogue that interacts with mitochondria and the tyrosine kinase adaptor SHC1, has shown the ability to inhibit certain aspects of microglial activation in laboratory studies. A recent study in Cells explored its acute effects on gene expression in a mouse model of TBI.
Study Design and Approach
Researchers used controlled cortical impact to induce TBI in adult male mice. They administered idebenone after injury and analyzed gene expression in the peri-lesional cortex at 24 hours using the NanoString Neuropathology Panel. The goal was to determine whether idebenone could moderate TBI-related transcriptomic changes, particularly those linked to microglial responses.
Key Findings on Microglial and Pathway Changes
TBI increased the expression of microglial activation signature genes. Unexpectedly, post-injury idebenone further elevated several of these microglial genes, suggesting it may enhance the early microglial response or microglial numbers in the first 24 hours after injury.
At the same time, idebenone significantly attenuated TBI-driven disruptions in gene expression related to behavior. The most strongly affected pathways were “ephrin receptor signaling” and “dopamine metabolic process.” Gene co-expression analysis linked higher levels of microglial complement component 1q (C1q) and the neurotrophin receptor gene Ntrk1 to large (>3-fold) TBI-induced drops in dopamine receptor genes Drd1 and Drd2—changes that idebenone helped reverse.
Bioinformatics analysis pointed to SUZ12 as a candidate transcriptional regulator of the gene expression shifts modified by idebenone.
Implications for TBI Treatment
These results indicate that idebenone does more than simply suppress inflammation. By amplifying certain early microglial signals while protecting ephrin-A and dopamine signaling pathways, it may offer functional neuroprotection in the acute phase of TBI. The identification of ephrin-A and dopamine pathways as novel idebenone targets opens new avenues for research into mitochondrial-targeted therapies for brain injury.